Oncogenic Y‐box binding protein‐1 as an effective therapeutic target in drug‐resistant cancer
| العنوان: | Oncogenic Y‐box binding protein‐1 as an effective therapeutic target in drug‐resistant cancer |
|---|---|
| المؤلفون: | Kosuke Watari, Michihiko Kuwano, Mayumi Ono, Tomohiro Shibata |
| المصدر: | Cancer Science |
| بيانات النشر: | John Wiley and Sons Inc., 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | 0301 basic medicine, Male, Transcriptional Activation, Cancer Research, Antineoplastic Agents, Drug resistance, Review Article, Growth Factor Receptor Gene, 03 medical and health sciences, 0302 clinical medicine, Neoplasms, oncogenic effector, Humans, Gene Regulatory Networks, Molecular Targeted Therapy, Phosphorylation, Transcription factor, Protein kinase B, Review Articles, Cell Nucleus, drug resistance, Kinase, Chemistry, Y‐box binding protein‐1, General Medicine, Y box binding protein 1, malignant progression, Prognosis, Androgen receptor, Gene Expression Regulation, Neoplastic, 030104 developmental biology, Oncology, Drug Resistance, Neoplasm, 030220 oncology & carcinogenesis, Cancer cell, Cancer research, overcoming drug resistance, Female, Y-Box-Binding Protein 1 |
| الوصف: | Y-box binding protein-1 (YBX1), a multifunctional oncoprotein containing an evolutionarily conserved cold shock domain, dysregulates a wide range of genes involved in cell proliferation and survival, drug resistance, and chromatin destabilization by cancer. Expression of a multidrug resistance-associated ATP binding cassette transporter gene, ABCB1, as well as growth factor receptor genes, EGFR and HER2/ErbB2, was initially discovered to be transcriptionally activated by YBX1 in cancer cells. Expression of other drug resistance-related genes, MVP/LRP, TOP2A, CD44, CD49f, BCL2, MYC, and androgen receptor (AR), is also transcriptionally activated by YBX1, consistently indicating that YBX1 is involved in tumor drug resistance. Furthermore, there is strong evidence to support that nuclear localization and/or overexpression of YBX1 can predict poor outcomes in patients with more than 20 different tumor types. YBX1 is phosphorylated by kinases, including AKT, p70S6K, and p90RSK, and translocated into the nucleus to promote the transcription of resistance- and malignancy-related genes. Phosphorylated YBX1, therefore, plays a crucial role as a potent transcription factor in cancer. Herein, a novel anticancer therapeutic strategy is presented by targeting activated YBX1 to overcome drug resistance and malignant progression. |
| اللغة: | English |
| تدمد: | 1349-7006 1347-9032 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2056b68f692acf430ba83662f512ac9 http://europepmc.org/articles/PMC6500994 |
| Rights: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....e2056b68f692acf430ba83662f512ac9 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 13497006 13479032 |
|---|